NEXT GENERATION INVESTMENT BANKING

Members network
Limited Mobile Version
WNT

WntResearch

Today
Day High
22.40
21.1
Day Low
20.20
Day Open
22.40
Prev Close
21.90
VWAP
N/A
Volume
34K
Turnover
0.723M
Top Broker
VWAP
22.2
Avg Volume
51K
Avg Turnover
1.134M
Top Brokers
AVA/NON
VWAP
22.5
Avg Volume
42K
Avg Turnover
0.943M
Top Brokers
AVA/NON
VWAP
23.7
Avg Volume
31K
Avg Turnover
0.744M
Top Brokers
AVA/MLI
52 week summary
Price Range
19.0
Last
49.4
Beta
N/A
Market Cap
360.3M
Total Return
-3.5%
Trailing P/E
N/A
Div Yield
N/A%
Shares Outstanding
17.1M
Next Earnings Date
18 May
Stock Exchange
Aktietorget
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months -32.4%
Change 12 Months -20.3%
Volume Trend
Average Volume 10 vs 60 Days 16.0%
Price VS
52 Week High -57.3%
50 Day Moving Average -17.2%
200 Day moving Average -25.0%

Add article markers

Compare WntResearch to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Henrik Lawaetz, CEO
  • Executive board
  • Peter Ström, Chairman of the board
Source: Millistream
Major Owners Equity Votes
Avanza Pension 13.5%
13.5%
Nordnet Pensionsförsäkring 11.0%
11.0%
Kjell Stenberg 8.1%
8.1%
Tommy Andersson 6.3%
6.3%
Lars-Erik Forsgårdh 2.8%
2.8%
Source: Millistream
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
+ 0
0 Sales
- 0
Last 24 weeks
0 Purchases
+ 0
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Redeye
Source: Redeye

Peer Group

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.


Karo Pharmaicon-close

Redeye Rating

Karo Pharma is not rated

Kanceraicon-close

Redeye Rating

Kancera is not rated

Bioinvent Internationalicon-close

Redeye Rating

6.0
5.0
5.5
0.0
1.0
PledPharmaicon-close

Redeye Rating

6.0
5.0
4.5
0.0
2.0
Immunicumicon-close

Redeye Rating

6.0
4.0
4.5
0.0
1.0